Influence of different fat emulsion-based intravenous formulations on the pharmacokinetics and pharmacodynamics of propofol von COX, E. H, KNIBBE, C. A. J, KOSTER, V. S, LANGEMEIJER, M. W. E, TUKKER, E. E, LANGE, R, KUKS, P. F. M, LANGEMEIJER, H. J. M, LIE-A-HUEN, L, DANHOF, M

Volltext

Pharmacokinetics, induction of anaesthesia and safety characteristics of Propofol 6% SAZN vs Propofol 1% SAZN and Diprivan®‐10 after bolus injection von Knibbe, Catherijne A. J., Voortman, Henk‐Jan, Aarts, Leon P. H. J., Kuks, Paul F. M., Lange, Rogier, Langemeijer, Han J. M., Danhof, Meindert

Volltext

Treatment with the platelet-activating factor antagonist TCV-309 in patients with severe systemic inflammatory response syndrome: a prospective, multi-center, double-blind, randomi... von Froon, A M, Greve, J W, Buurman, W A, van der Linden, C J, Langemeijer, H J, Ulrich, C, Bourgeois, M

Volltext

Rupture recurrence after surgical repair of postinfarction ventricular septal rupture. Influence of early thrombolysis von Cox, F F, Morshuis, W J, Kelder, J C, Plokker, H W, Langemeijer, H J, Vermeulen, F E

Volltext

TREATMENT WITH THE PLATELET-ACTIVATING FACTOR ANTAGONIST TCV-309 IN PATIENTS WITH SEVERE SYSTEMIC INFLAMMATORY RESPONSE SYNDROME: A PROSPECTIVE, MULTI-CENTER, DOUBLEBLIND, RANDOMIZ... von Froon, Albert M.F., Greve, Jan Willem M., Buurman, Wim A., van der Linden, Cees J., Langemeijer, Han J.M., Ulrich, Chris, Bourgeois, Marc

Volltext